Sera Prognostics, Inc.
SERAHealthcareNASDAQMedical Devices
Scan Results
Daily timeframePart of the healthcare sector, Sera Prognostics, Inc. (SERA) is listed under Medical Devices. The company carries a $79.3M market cap, placing it firmly in the micro-cap category. The company develops the PreTRM test, a non-invasive blood test given to a pregnant woman, carrying a single fetus, during weeks 18 through 20 of gestation.
Market Cap
$79.3M
Beta
0.98
P/E (TTM)
—
P/E (Fwd)
-3.76
EPS (TTM)
$-0.66
EPS (Fwd)
$-0.54
ROE
-45.0%
ROA
-23.5%
Cash
$46.4M
Total Debt
$3.0M
Free CF
-$18.9M
52W Change
-34.8%
Annual Financials
Cash vs Debt
Where SERA stands vs its 150-day and 200-day moving averages
As of the September 3, 2026 close, SERA finished 3.37% below its 150-day moving average ($2.08) and 15.90% below its 200-day moving average ($2.39). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is SERA overbought or oversold?
At the September 3, 2026 close, SERA's RSI(14) was 50.0, in neutral territory (between 30 and 70). The MACD histogram was negative, so short-term momentum leaned bearish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
The balance sheet looks solid with $46.4M in cash comfortably exceeding the $3.0M debt load. A net cash position generally provides financial flexibility during uncertain economic periods. Free cash flow is running at -$18.9M, which bears watching. Negative free cash flow can be acceptable during heavy investment periods but needs to improve over time. Return on equity stands at -45.0%, which is negative for the sector. ROE measures how effectively a company uses shareholder capital to generate profits. Revenue has been uneven over recent years, ranging from $268K to $81K.
With cash comfortably exceeding debt, SERA has financial flexibility that may help navigate uncertain periods. Negative free cash flow means the company is currently spending more than it generates, which may require future fundraising or debt if the trend continues. Understanding these risk dimensions helps frame what to watch going forward as conditions evolve for Sera Prognostics, Inc. and its sector.